Compare Eli Lilly and Johnson & Johnson and Pfizer in the following categories: revenue growth rate, earnings reports, net income, tax rate, operating margin, gross profit margin, R&D investment

Eli Lilly, Johnson & Johnson, and Pfizer have all released their latest earnings reports for Q3 2023. Here's a comparison of the key financial metrics:
1. Revenue growth rate: Eli Lilly has the highest year-on-year revenue growth rate at 36.84%, followed by Johnson & Johnson at 6.78%, and Pfizer at -41.55% (due to the impact of the pandemic on vaccine sales).
2. Earnings reports: All three companies have reported strong earnings, with Johnson & Johnson and Eli Lilly posting net incomes of $26.028 billion and $9.498 billion, respectively. Pfizer, however, reported a net loss of $2.376 billion due to the same vaccine sales impact.
3. Net income: As mentioned above, Johnson & Johnson and Eli Lilly have both reported strong net incomes, while Pfizer reported a net loss.
4. Tax rate: All three companies have reported similar effective tax rates, with Johnson & Johnson at 6.78%, Eli Lilly at 7.86%, and Pfizer at 60.7%.
5. Operating margin: Eli Lilly has the highest operating profit margin at 78.63%, followed by Johnson & Johnson at 69.02%, and Pfizer at 60.7%.
6. Gross profit margin: All three companies have reported strong gross profit margins, with Johnson & Johnson at 69.02%, Eli Lilly at 78.63%, and Pfizer at 60.7%.
7. R&D investment: Unfortunately, specific R&D investment figures were not provided in the earnings reports. However, it's worth noting that all three companies are heavily invested in research and development to drive future growth.

Overall, while each company has its strengths and weaknesses, all three have reported strong financial performance in Q3 2023.